You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: June 23, 2024

ZYRTEC HIVES RELIEF Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Zyrtec Hives Relief patents expire, and what generic alternatives are available?

Zyrtec Hives Relief is a drug marketed by J And J Consumer Inc and is included in one NDA.

The generic ingredient in ZYRTEC HIVES RELIEF is cetirizine hydrochloride. There are thirty-nine drug master file entries for this compound. One hundred and fifty-four suppliers are listed for this compound. Additional details are available on the cetirizine hydrochloride profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Zyrtec Hives Relief

A generic version of ZYRTEC HIVES RELIEF was approved as cetirizine hydrochloride by PADAGIS US on June 17th, 2008.

  Sign Up

Drug patent expirations by year for ZYRTEC HIVES RELIEF
Recent Clinical Trials for ZYRTEC HIVES RELIEF

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Emory UniversityPhase 4
Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare DivisionPhase 1
Indiana UniversityPhase 4

See all ZYRTEC HIVES RELIEF clinical trials

Pharmacology for ZYRTEC HIVES RELIEF

US Patents and Regulatory Information for ZYRTEC HIVES RELIEF

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
J And J Consumer Inc ZYRTEC HIVES RELIEF cetirizine hydrochloride TABLET;ORAL 019835-005 Nov 16, 2007 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
J And J Consumer Inc ZYRTEC HIVES RELIEF cetirizine hydrochloride TABLET;ORAL 019835-006 Nov 16, 2007 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for ZYRTEC HIVES RELIEF

See the table below for patents covering ZYRTEC HIVES RELIEF around the world.

Country Patent Number Title Estimated Expiration
Cyprus 1307 2-(4-(DIPHENYLMETHYL)-1-PIPERAZINYL)-ACETIC ACIDS AND THEIR AMIDES,PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS ⤷  Sign Up
Denmark 154078 ⤷  Sign Up
Greece 75407 ⤷  Sign Up
Denmark 5388 ⤷  Sign Up
Denmark 155796 ⤷  Sign Up
Spain 8307776 ⤷  Sign Up
Yugoslavia 43511 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for ZYRTEC HIVES RELIEF

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0663828 C300085 Netherlands ⤷  Sign Up PRODUCT NAME: LEVOCETIRIZINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER LEVOCETIRINE DIHYDROCHLORIDE; NAT. REGISTRATION NO/DATE: RVG 26770 20011009; FIRST REGISTRATION: DE 49903.00.00 AND 49904.00.00 20010103
0058146 SPC/GB01/052 United Kingdom ⤷  Sign Up SPC/GB01/052:, EXPIRES: 20070205
0058146 2001C/045 Belgium ⤷  Sign Up PRODUCT NAME: DICHLORHYDRATE DE LEVOCETIRIZINE; NAT RER. NO/DATE: 194 IS 90 F3 20011022; FIRST REG.: DE 49903.00.00 20010103
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.